Abstract

Angiogenesis and signaling through the RASlRAF/mitogen-activated protein/extracellular signal-regulated kinase (ERK) kinase (MEK)/ERKcascade have been reported to play important roles in the development of hepatocellular carcinoma (HCC). Sorafenib (Nexavar), a novel bi-aryl urea SAY 43-9006, is an orally administered multikinase inhibitor with activity against RASIRAF kinases multikinase inhibitor with activity against RAP kinases and several receptor tyrosine kinases, including vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor (pDGFR), FLT3, Ret, and c-Kit. It is involved in angiogenic pathway and cell proliferation. Sorafenib has demonstrated potent anti-tumor activity in in vitro studies, preclinical xenograft models of different tumor types and human clinical trials. This review summarizes the history of sorafenib from its discovery by the medicinal chemistry approach through to clinical development and ongoing trials on the combination between sorafenib and trans-arterial chemoembolization (TACE) in HCC patients.

Autore Pugliese

• Rizzo Annalisa , Sciorsci Raffaele Luigi

Tutti gli autori

• RIZZO A.;SCIORSCI R.L.

Titolo volume/Rivista

Non Disponibile

Anno di pubblicazione

2012

ISSN

0929-8673

ISBN

Non Disponibile

Numero di citazioni Wos

Nessuna citazione

Ultimo Aggiornamento Citazioni

Non Disponibile

Numero di citazioni Scopus

41

Ultimo Aggiornamento Citazioni

Non Disponibile

Settori ERC

Non Disponibile

Codici ASJC

Non Disponibile